Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

Rhythm Pharmaceuticals, Inc.57 sites in 4 countries5,966 target enrollmentSeptember 28, 2016

ConditionsPro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 5966
Locations: 57
Primary Endpoint: Identification of individuals with POMC, LepR or PCSK1 genetic mutations
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this screening study is to identify people who have a rare genetic cause of obesity - specifically three genetic variants (a change in the DNA structure) of the POMC, PCSK1 and LepR genes that are currently known to result in obesity.

This screening study will not include any investigational drugs. You will be asked to provide a DNA sample and answer some questions about your medical history and hunger.

Registry

clinicaltrials.gov

Start Date

September 28, 2016

End Date

June 9, 2020

Last Updated

3 years ago

Study Type

Observational

Sex

All